Baker McKenzie Advises a Consortium led by SPE Capital, and included EBRD, Proparco and BIO on their Investment in Leading Ophthalmic Pharmaceutical Manufacturer

Baker McKenzie has advised a consortium of investors led by SPE Capital, through its Private Equity Fund III (PEF III), on its investment in a European holding company, the parent company of Orchidia Pharmaceutical Industries S.A.E., a leading ophthalmic pharmaceutical manufacturer with operations in Egypt and across the Middle East and Africa.

The investor consortium included the European Bank for Reconstruction and Development (EBRD), Société de Promotion et de Participation pour la Coopération Économique (Proparco), and the Belgian Investment Company for Developing Countries (BIO). The transaction was successfully completed in March 2026.